IONS
Ionis Pharmaceuticals
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
News
- CHMP recommends TRYNGOLZA (olezarsen) for EU approval to treat severe hypertriglyceridemiaOct 16, 2026
- Ionis reports positive interim results from partner Roche's Phase 3 IMAgINATION study in IgA nephropathySep 23, 2026
- Ionis reports positive topline Phase 3 FUSION results for ulefnersen, advancing a potential first disease-modifying treatment for FUS-ALSSep 22, 2026
- Ionis received FDA approval for Zanvastro in Alexander disease, making it the first disease-modifying therapy for the rare disorderSep 7, 2026
- Ionis and partner Biogen presented Phase 2 CELIA data showing meaningful clinical benefits and strong tau reduction with Diranersen in early Alzheimer's diseaseJul 15, 2026